Join us in welcoming Robert Kalb, MD, the inaugural Director of the Les Turner ALS Research and Patient Center at Northwestern Medicine and Chief of Neuromuscular Medicine in the Ken & Ruth Davee Department of Neurology. Dr. Kalb has spent …
Cytokinetics Announces Negative Results from VITALITY-ALS
Cytokinetics announced the endpoints for the clinical trial of tirasemtiv (VITALITY-ALS) had not been met and that further development of the drug was being suspended. We share Cytokinetics, and your, disappointment in this announcement and are grateful for Cytokinetics continued …
7th Annual Les Turner Symposium on ALS and NeuroRepair
The 7th Annual Les Turner Symposium on ALS and NeuroRepair will held on Monday, November 6 at Prentice Women’s Hospital. Celebrating research, patient care and education–attendees will get the opportunity to learn the latest on ALS drug development. Christopher Henderson, …
Meet the Director of the Les Turner ALS Research and Patient Center at Northwestern Medicine
It is our great pleasure to announce that Robert Kalb, MD from the University of Pennsylvania has been selected as the first Director of the Les Turner ALS Research and Patient Center at Northwestern Medicine, Chief of Division of Neuromuscular …
Collaboration in Research
A recent publication in Neurology Today highlights the research of Dr. Sabrina Paganoni who is testing a drug to slow the progression of ALS. This study is being done in collaboration with Les Turner ALS Research and Patient Center at Northwestern Medicine …
Evidence for an early innate immune response in the motor cortex of ALS.
A new publication about the role of immunity in ALS, authored by members of the Les Turner ALS Research and Patient Center at Northwestern Medicine, has been issued. Read on for a Q&A with Dr. P. Hande Ozdinler, one of …
Investing in our Future: Funding ALS Research
Each year, the Les Turner ALS Foundation provides a grant to the Les Turner ALS Research and Patient Center at Northwestern Medicine. This grant provides support to the Lois Insolia ALS Clinic as well as researchers looking for answers on …
Radicava FAQs
Les Turner ALS Research and Patient Center at Northwestern Medicine On May 5, the FDA approved a new drug to treat ALS. Radicava™ (also known as Edaravone) is the first approved ALS-specific drug since Riluzole, which was approved 22 years …
New Gene Identified in ALS
(May 15, 2017)- For the first time, a variant in UBQLN4 gene has been associated with Lou Gehrig’s disease or amyotrophic lateral sclerosis (ALS) – a progressive disease resulting in the loss of nerve cells that control muscle movement, which …
The National ALS Biorepository Launched – “Learn How to Participate”
One of the questions that people living with ALS often ask is – what can I do to help ALS Research? ALS patients can do that, with a personal contribution to the National ALS Registry (Registry) – in the newly …
